Wil jij tips en tricks om gezonder te leven?

Lees ons laatste blog



DoctorPill.com helpt je gezond te blijven

Ik wil mensen helpen slank, fit en gezond te blijven en weet ondertussen dat ik een roepende in de woestijn ben. Ik ben zo lang bezig geweest om mensen blijvend in beweging te krijgen én slank en gezond te houden. Het is me niet gelukt, maar er is verandering op komst.

Samen met een team van experts, heb ik al mijn kennis en ervaring op het gebied van voeding supplementen, vitaminen, mineralen en anti-oxidanten gestopt in de DoctorPill.com producten. We hebben ons laten leiden door voortschrijdende kennis en zoveel als mogelijk wetenschappelijk onderbouwing gezocht  om tot de samenstelling van de diverse producten te komen. Producten die het makkelijker maken af te slanken en fitter te worden en daardoor je helpen om minder ongezond te gaan leven. Pillen die je helpen om slaapproblemen het hoofd te bieden en daardoor beter te herstellen, die helpen je trek en zoetzucht beter te beheersen en helpen je stofwisseling aan het werk te zetten zodat je meer vet kunt verbranden. Oók zónder veel discipline en doorzettingsvermogen. En zelfs de gevolgen van uitspattingen op een feest sneller helpen te herstellen.

‘You live your life; we'll look after you.’


Guus van der Meer


DoctorPill.com Producten



Neem contact op

Studie 1
Studie 2
Studie 3

Studie 1

Efficacy and tolerability of a novel herbal formulation for weight management.



To evaluate the efficacy of an herbal blend.


A randomized, double-blind, clinical trial in 60 subjects with body mass index (BMI) between 30 and 40 kg/m(2) .

Lees meer

Participants were randomized into two groups receiving either 400 mg herbal capsules or 400 mg placebo capsules twice daily. The herbal blend comprises of extracts from Sphaeranthus indicus and Garcinia mangostana. Participants received a standard diet (2,000 kcal per day) and walked 30 min 5 days per week.


After 8 weeks, significant net reductions in body weight (3.74 kg; P < 0.0001), BMI (1.61 kg/m(2) ; P < 0.0001), and waist circumference (5.44 cm; P < 0.05) were observed in the herbal group compared with placebo. Additionally, a significant increase in serum adiponectin concentration was found in the herbal group versus placebo (P = 0.001). Adverse events were mild and were equally distributed between the two groups. In vitro studies in the 3T3-L1 adipocyte cell line showed that the herbal extract markedly downregulated the expression of peroxisome proliferator-activated receptor gamma, adipocyte-differentiation related protein, and cluster of differentiation 36 but increased adiponectin expression. The herbal extract also reduced the expression and the recruitment of perilipin onto the membrane of lipid droplets.


Supplementation with the herbal blend resulted in a greater degree of weight loss than placebo over 8 weeks.

Copyright © 2012 The Obesity Society.

Studie 2

Acute versus chronic partial sleep deprivation in middle-aged people: differential effect on performance and sleepiness.



To evaluate the effects of acute sleep deprivation and chronic sleep restriction on vigilance, performance, and self-perception of sleepiness.


Habitual night followed by 1 night of total sleep loss (acute sleep deprivation) or 5 consecutive nights of 4 hr of sleep (chronic sleep restriction) and recovery night.


Eighteen healthy middle-aged male participants (age [(± standard deviation] = 49.7 ± 2.6 yr, range 46-55 yr).


Lees meer

Multiple sleep latency test trials, Karolinska Sleepiness Scale scores, simple reaction time test (lapses and 10% fastest reaction times), and nocturnal polysomnography data were recorded.

RESULTS: Objective and subjective sleepiness increased immediately in response to sleep restriction. Sleep latencies after the second and third nights of sleep restriction reached levels equivalent to those observed after acute sleep deprivation, whereas Karolinska Sleepiness Scale scores did not reach these levels. Lapse occurrence increased after the second day of sleep restriction and reached levels equivalent to those observed after acute sleep deprivation. A statistical model revealed that sleepiness and lapses did not progressively worsen across days of sleep restriction. Ten percent fastest reaction times (i.e., optimal alertness) were not affected by acute or chronic sleep deprivation. Recovery to baseline levels of alertness and performance occurred after 8-hr recovery night.


In middle-aged study participants, sleep restriction induced a high increase in sleep propensity but adaptation to chronic sleep restriction occurred beyond day 3 of restriction. This sleepiness attenuation was underestimated by the participants. One recovery night restores daytime sleepiness and cognitive performance deficits induced by acute or chronic sleep deprivation.


Philip P; Sagaspe P; Prague M; Tassi P; Capelli A; Bioulac B; Commenges D; Taillard J. Acute versus chronic partial sleep deprivation in middle-aged people: differential effect on performance and sleepiness. SLEEP 2012;35(7):997-1002.

Studie 3

Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review.


Epidemiological studies have proved that, there are pathophysiological connections between Type 2 Diabetes Mellitus (T2DM) and Alzheimer's disease (AD). Diabetic patients have higher incidences of cognitive impairment and hence they are more at the risk of developing AD. Some of the recent evidences have majorly stated the effects of insulin resistance in the disturbance of various biological processes and signaling pathways.

Lees meer

Both hyperglycemia and hypoglycemic conditions contributes in dysfunctioning of cognitive abilities and functions. The present review summarizes the evidences which establish the possible links between the two pathologies on the account of molecular, biochemical and at histopathological level. The information regarding their interactions was collected from different databases and journals. The gathered information will clearly establish the link among the two pathologies and will be helpful in future for the development of drugs for Type 3 Diabetes.

Copyright © 2016. Published by Elsevier Ltd.